APRINOIA Therapeutics, a Phase 3 biotech developing diagnostics and therapies for neurodegenerative diseases, withdrew its plans for an initial public offering on Monday. It originally filed in January 2024 and most recently planned to raise $6 million by offering 0.5 million shares at a price range of $10 to $12.
The Cambridge, MA-based company was founded in 2015 and booked $9 million in revenue for the 12 months ended December 31, 2023. It had planned to list on the Nasdaq under the symbol APRI. Kingswood Capital Markets and WallachBeth Capital were set to be the joint bookrunners on the deal.
